SLN Silence Therapeutics
- 22.950
- +0.350+1.55%
Silence Therapeutics News
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaining 0.35% to 1,403.4 on the S&P Europe Select ADR Index. From continental Europe, the gainers were le
Silence Therapeutics Files to Sell 5.71M American Depositary Shares for Holders
Silence Therapeutics Announces Board Change
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
Silence Therapeutics Announces Retirement of Alistair Gray From Board of Directors
Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their
Silence Therapeutics Is Maintained at Overweight by Morgan Stanley
Silence Therapeutics Is Maintained at Overweight by Morgan Stanley
Damo: Maintaining the Silence Therapeutics (SLN.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $45.00 to $45.00.
Damo: Maintaining the Silence Therapeutics (SLN.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $45.00 to $45.00.
Morgan Stanley Maintains Overweight on Silence Therapeutics, Maintains $45 Price Target
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and maintains $45 price target.
Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Touched US$1.1b Last Week, Benefiting Both Retail Investors Who Own 27% as Well as Institutions
Key Insights Silence Therapeutics' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 54% of the business is held by the top
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,330.20 on the S&P Europe Select ADR Index. Despite the gain, the index remains
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were lower Tuesday morning, declining 0.67% to 1,332.69 on the S&P Europe Select ADR Index. From continental Europe, the gainers were
Silence Therapeutics Announces Upcoming AGM
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week trending moderately higher Monday morning, rising 0.53% to 1,352.74 on the S&P Europe Select ADR Index. From cont
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
European equities traded in the US as American depositary receipts were lower Friday morning, falling 0.66% to 1,356.48 on the S&P Europe Select ADR Index. The index is poised to close the week down n
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects With Elevated Lipoprotein(a)
Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosing Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading
European equities traded in the US as American depositary receipts were trending slightly higher late Wednesday morning, rising 0.18% to 1,370.27 on the S&P Europe Select ADR Index. From continental E
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading
European equities traded in the US as American depositary receipts opened the week modestly lower Monday morning, declining 0.23% to 1,353.40 on the S&P Europe Select ADR Index. From continental Europ
Brokers Are Upgrading Their Views On Silence Therapeutics Plc (NASDAQ:SLN) With These New Forecasts
Shareholders in Silence Therapeutics plc (NASDAQ:SLN) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts greatly increased thei
Analysts Are Upgrading Silence Therapeutics Plc (NASDAQ:SLN) After Its Latest Results
Analysis
Price Target
No Data
